ERBB2 and breast carcinoma: They demonstrated its effectiveness in increasing drug-induced cytotoxicity in specific tamoxifen therapies for estrogen receptor (ER) in MCF7 breast cancer cell lines and lapatinib therapy for HER2 in BT474 breast cancer cell lines.